MetaCap

ImmunityBio (IBRX) vs Twist Bioscience (TWST)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Twist Bioscience (TWST) has outperformed ImmunityBio (IBRX) over the past year, gaining 261.8% versus a gain of 189.4%. Over five years, TWST leads with a +8.8% price change compared with -7.4% for IBRX. Twist Bioscience is the larger company by market cap ($7.04 billion vs $6.40 billion), about 1.1 times the size, while ImmunityBio is growing revenue faster (+668.3% vs +22.0%).

Twist Bioscience converts more of its revenue into profit, with a net margin of -28.3% versus -310.2%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IBRX+189.42%TWST+261.76%
+649%+306%-36%
Nov 21, 20251 yearNov 20, 2026
IBRX-6.38%TWST-6.60%
+79%-9%-97%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IBRX versus TWST key metrics
MetricIBRXTWST
Share price$6.02$103.32
Market cap$6.40B$7.04B
1-day change-8.37%-7.44%
YTD return+204.04%+225.73%
1-year return+189.42%+261.76%
5-year return-7.38%+8.77%
EPS (TTM)$-1.06$-2.08
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$113.29M$459.43M
Revenue growth (YoY)+668.31%+22.00%
Net income (latest FY)$-351.40M$-130.20M
Gross margin99.34%52.41%
Operating margin-226.00%-30.35%
Net margin-310.18%-28.34%
52-week high$12.43$219.71
52-week low$1.95$28.27
Distance from 52-week high-51.57%-52.97%
Analyst consensusstrong_buybuy
Avg. price target upside+136.71%+24.68%
Average volume12.97M2.49M
Shares outstanding1.06B68.18M
Employees6841,080
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TWST has outperformed IBRX by 72.3 percentage points over the past year.
  • Twist Bioscience is more profitable, keeping -28.3 cents of every revenue dollar as net income versus -310.2 cents for ImmunityBio.
  • ImmunityBio grew revenue faster in its latest fiscal year (+668.31% vs +22.00%).

About ImmunityBio

IBRX stock →

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 684 employees

About Twist Bioscience

TWST stock →

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; and Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, and other applications.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,080 employees

IBRX vs TWST FAQ

Which is bigger, ImmunityBio or Twist Bioscience?

Twist Bioscience (TWST) is larger, with a market capitalization of $7.04B compared with $6.40B for ImmunityBio (IBRX).

Which stock has performed better over the past year, IBRX or TWST?

TWST returned +261.76% over the past 12 months, compared with +189.42% for IBRX (price return, excluding dividends). Past performance does not predict future results.

Are ImmunityBio and Twist Bioscience in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons